Compare Orion Office REIT Inc (ONL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Orion Office REIT Inc trades at $2.21 (market cap $125.50M), while State Street SPDR S&P Biotech ETF trades at $154.31 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 80.6× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 33 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| ONL | XBI | |
|---|---|---|
Market Cap | $125.50M | $10.11B |
Volume | 303,276 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $3.00 | $169.55 |
52-Week Low | $1.93 | $104.99 |
Typical Hold Time | 33 Days | 37 Days |
Enterprise Value | $542.43M | — |
Dividend Yield | 3.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.20, down 3.08% with a bearish technical signal despite oscillators showing some bullish momentum. The company shows declining revenue from $208M in 2022 to $148M in 2025 with persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics show low P/S (0.88) and P/B (0.2) ratios, while analyst sentiment is split evenly between Buy and Hold recommendations.
The outlook remains challenging with ongoing revenue declines and negative profitability, though deep valuation discounts and strategic portfolio repositioning offer potential upside. Key risks include high debt levels, office sector headwinds, and execution challenges in turning around financial performance.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
